Moxifloxacin as an Adjunctive Antibiotic in the Treatment of Severe Chronic Periodontitis

Background: The impact of moxifloxacin (MOX) was analyzed in the treatment of severe chronic periodontitis. Methods: In a randomized, prospective, clinical multicenter trial, 92 subjects with severe chronic periodontitis were treated with scaling and root planing (SRP) alone (control group; n = 21), SRP plus adjunctive doxycycline (DOX group; n = 36), or SRP plus adjunctive MOX (MOX group; n = 35). Probing depth (PD), clinical attachment level (CAL), and bleeding on probing (BOP) were recorded at baseline and at 3, 6, and 12 months after non‐surgical periodontal treatment. The load of periodontopathogens, the level of interleukin‐8, and the activities of granulocyte elastase and myeloperoxidase were also measured. Results: All three procedures led to significant reductions in PD, CAL, and BOP. PD reduction was significantly greater (P